Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Return on Sales (2016 - 2025)

Historic Return on Sales for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to 0.61%.

  • Perspective Therapeutics' Return on Sales fell 10000.0% to 0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61%, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of 0.67% for FY2024, which is 56400.0% up from last year.
  • Perspective Therapeutics' Return on Sales amounted to 0.61% in Q3 2025, which was down 10000.0% from 3.01% recorded in Q2 2025.
  • Over the past 5 years, Perspective Therapeutics' Return on Sales peaked at 3.01% during Q2 2025, and registered a low of 2.37% during Q3 2022.
  • Its 5-year average for Return on Sales is 0.28%, with a median of 0.57% in 2021.
  • As far as peak fluctuations go, Perspective Therapeutics' Return on Sales plummeted by -17300bps in 2024, and later skyrocketed by 39800bps in 2025.
  • Over the past 5 years, Perspective Therapeutics' Return on Sales (Quarter) stood at 0.57% in 2021, then tumbled by -140bps to 1.37% in 2022, then skyrocketed by 177bps to 1.06% in 2023, then tumbled by -164bps to 0.67% in 2024, then soared by 191bps to 0.61% in 2025.
  • Its Return on Sales stands at 0.61% for Q3 2025, versus 3.01% for Q2 2025 and 0.37% for Q1 2025.